Molecular Templates (MTEM)
(Delayed Data from NSDQ)
$1.47 USD
-0.01 (-0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.30 -1.17 (-79.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.47 USD
-0.01 (-0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.30 -1.17 (-79.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Molecular Templates Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Molecular Templates
Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet
by Zacks Equity Research
Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.
7 Great Stocks for a Small Budget
by Sejuti Banerjea
Take advantage of panic selling with these 7 cheap stocks.
Will Molecular Templates Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Molecular Templates.
Analysts Estimate Molecular Templates (MTEM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Molecular Templates to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Molecular Templates.
Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
Will Molecular Templates Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Molecular Templates.
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
by Zacks Equity Research
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.
Moving Average Crossover Alert: Molecular Templates Inc. (MTEM)
by Zacks Equity Research
Moving Average Crossover Alert: Molecular Templates Inc. (MTEM)